<DOC>
	<DOCNO>NCT02126826</DOCNO>
	<brief_summary>- To investigate safety tolerability BI 1026706 male female healthy subject osteoarthritis ( OA ) patient follow oral administration repeat rise dos - To explore pharmacokinetics multiple rise dos BI 1026706 male female healthy subject OA patient - The assessment pharmacodynamics OA patient</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Oral Doses BI 1026706 Male Female Healthy Subjects Patients With Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Inclusion criterion : 1 . Males female without clinically relevant medical disorder accord investigator 's assessment , base following : complete medical history include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram , clinical laboratory test 2 . For OA patient : Evidence OA knee radiography magnetic resonance tomography ( KellgrenLawrence grade 1 , 2 , 3 ; exclude grade 0 4 ) knee ( tibiofemoral joint ) within last 5 year consistent clinical diagnosis osteoarthritis knee accord ACR ( American College Rheumatology ) guideline 3 . For OA patient : ARA ( American Rheumatism Association ) functional class I , II , III 4 . For OA patient : Average pain index knee previous 48 hour great equal 4 11item Likert scale two time point : 1 ) screening ( analgesic medication ) 3 day washout analgesic medication , 2 ) even prior randomisation 5 . For OA patient : Presence bothersome OA related pain day within last month prior screen investigator 's discretion , pain require analgesic treatment 3 day per week last month prior screen . 6 . Age 35 65 year ( inclusive ) 7 . BMI ( Body Mass Index ) 18.5 33 kg/m2 ( inclusive ) 8 . Signed date write informed consent prior admission study accordance GCP local legislation 9 . Females meet follow criterion least 30 day first study drug administration 30 day trial completion : use adequate contraception , e.g . follow method plus condom : implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) sexually abstinent vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) surgically sterilise ( include hysterectomy ) postmenopausal define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level FSH ( Follicle Stimulating Hormon ) 40 U/L estradiol 30 ng/L confirmatory ) Exclusion criterion : 1 . Any finding medical examination ( include Blood Pressure , Pulse Rate electrocardiogram ) deviate normal judge clinically relevant investigator 2 . Repeated measurement systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg 3 . Any laboratory value outside reference range investigator considers clinical relevance 4 . Any evidence concomitant disease judge clinically relevant investigator 5 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 6 . Surgery gastrointestinal tract could interfere kinetics study drug ( ) 7 . Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>